MehmetAsimBilenMD

Oncology • Atlanta, GA

Genitourinary Oncology

Director of Genitourinary Medical Oncology, Winship Cancer Institute of Emory University

Join to view full profile

Dr. Bilen is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Bilen's full profile

Already have an account?

Office
Winship Cancer Institute Of Emory University
Atlanta, GA 30322
Phone+1 404-778-3460

Summary

I serve as Assistant Professor in the Department of Hematology and Medical Oncology at Emory University School of Medicine. I joined the clinical staff at Winship Cancer Institute as a practicing physician in July 2016. I am actively involved in clinical research and patient care in the area of genitourinary cancers, and serve as the Associate Medical Director of the Phase I Unit at Winship Cancer Institute. I work closely with the Fellowship Program of the Department of Hematology and Medical Oncology by educating fellows on genitourinary oncology. I also serve on the Winship Clinical and Translational Review Committee and Grady Clinical Research Committee.
I hold professional memberships with American Association for Cancer Research and American Society of Clinical Oncology.

Education & Training

University of Texas Health Science Center at Houston/M D Anderson Cancer CenterFellowship, Hematology and Medical Oncology, 2013 - 2016
Baylor College of MedicineResidency, Internal Medicine, 2010 - 2013
Hacettepe University FOMClass of 2008

Certifications & Licensure

GA State Medical License 2016 - 2025
American Board of Internal Medicine Medical Oncology

Clinical Trials

A Phase 1, Dose-Escalation Trial of PT2385 Tablets In Patients With Advanced Clear Cell Renal Cell Carcinoma (MK-3795-001) Start of enrollment: 2014 Nov 25
Active, not recruiting
Phase 1
An Investigational Immuno-therapy Study of Experimental Medication BMS-986156, Given by Itself or in Combination With Nivolumab in Patients With Solid Cancers or Cancers That Have Spread. Start of enrollment: 2015 Oct 14
Completed
Phase 1, Phase 2
A Study of Avelumab With Axitinib Versus Sunitinib In Advanced Renal Cell Cancer (JAVELIN Renal 101) Start of enrollment: 2016 Mar 23
Active, not recruiting
Phase 3
Darolutamide in Addition to Standard Androgen Deprivation Therapy and Docetaxel in Metastatic Hormone-Sensitive Prostate Cancer Start of enrollment: 2016 Nov 30
Completed
Phase 3
A Study to Evaluate the Efficacy and Safety of Pemigatinib (INCB054828) in Subjects With Urothelial Carcinoma - (FIGHT-201) Start of enrollment: 2017 Jan 12
Completed
Phase 2
A Dose Escalation and Cohort Expansion Study of NKTR-214 in Combination With Nivolumab and Other Anti-Cancer Therapies in Patients With Select Advanced Solid Tumors Start of enrollment: 2016 Dec 19
Completed
Phase 1, Phase 2
Gallium Ga 68-DOTATATE PET/CT in Diagnosing Patients With Metastatic Castration Resistant Prostate Cancer Start of enrollment: 2018 Feb 22
Completed
Phase 2
Neoadjuvant Cabozantinib in Treating Patients With Locally Advanced Kidney Cancer Start of enrollment: 2019 Aug 06
Active, not recruiting
Phase 2
Cabozantinib in Combination With Enfortumab Vedotin for Locally Advanced or Metastatic Urothelial Cancer Start of enrollment: 2021 Jul 23
Recruiting
Phase 1
Roles: Contact, Principal Investigator
Join now to see all

Publications & Presentations

PubMed

4 citations
Understanding and overcoming resistance to immunotherapy in genitourinary cancers.
Sean T Evans, Yash Jani, Caroline S Jansen, Ahmet Yildirim, Ecem Kalemoglu
Cancer Biology & Therapy. 2024-12-31
Blood-based tumor mutational burden impacts clinical outcomes of immune checkpoint inhibitor treated breast and prostate cancers.
Reagan M Barnett, Albert Jang, Sree Lanka, PIngfu Fu, Leslie A Bucheit
Communications Medicine. 2024-12-02
Differentiation fate of a stem-like CD4 T cell controls immunity to cancer.
Maria A Cardenas, Nataliya Prokhnevska, Ewelina Sobierajska, Petra Gregorova, Christopher B Medina
Nature. 2024-12-01

Journal Articles

The Addition of Chemotherapy in the Definitive Management of High Risk Prostate Cancer
Bradley C Carthon, Mehmet A Bilen, Omer Kucuk, Urologic Oncology

Authored Content

Cabozantinib for the Treatment of Patients with Metastatic Non-Clear Cell Renal Cell Carcinoma: A Retrospective AnalysisNovember 2018
The Addition of Chemotherapy in the Definitive Management of High Risk Prostate CancerOctober 2018

Press Mentions

Immune Cell Find Boosts Cancer Immunotherapy HopesOctober 26th, 2024
Immune Cell Discovery Offers New Potential for Cancer ImmunotherapyOctober 25th, 2024
Cancer Clinical Trials Are a Win for Patients, Doctors & ResearchersJuly 5th, 2022
Join now to see all

Grant Support

Osteocrines in Therapy Resistance of Prostate Cancer Bone Metastasis: Evaluation of Strategies to Overcome Therapy Resistance from Tumor-Educated Bone Environment.Special Challenge Award - Prostate Cancer Foundation-JanssenPresent